Krystal Biotech is engaged in developing genetic medicines. The biotech stock is near a buy point with earnings due soon.

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

CalciMedica had been evaluating the therapy, called Auxora, in the Kourage trial of patients with stage 2 or 3 AKI with ...